首页 > 最新文献

Clinical Transplantation最新文献

英文 中文
The Role of Liver Biopsy Findings in Uncontrolled Donation After Circulatory Death a 4-Year Single-Center Experience 肝活检结果在循环性死亡后非受控捐献中的作用——4年单中心研究
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-06 DOI: 10.1111/ctr.70431
Luca Novelli, Chiara Lazzeri, Davide Ghinolfi, Manuela Bonizzoli, Tiziana Tatti, Luca Messerini, Giuseppe Feltrin, Adriano Peris

Background

Uncontrolled donors after circulatory death (uDCDs) are recognized as a potential donor pool. No data are so far available on liver biopsy findings in uDCDs. We aimed at assessing liver biopsy findings in uDCDs consecutively admitted to our Center from 2019 to 2023.

Methods

Twenty nine utilized uDCD consecutively admitted at our Center from 2019 to 2023 were included. Liver biopsies were performed during organ procurement in all uDCDs.

Results

The median time from cardiac arrest to normothermic regional perfusion (NRP) run was 144 min, while the median NRP duration was 6 h. The liver was retrieved but not transplanted in 12 donors (12/29, 41%) and transplanted in 10 donors (10/29, 35%). In 7 uDCDs, livers were not retrieved (24%). Ishak grading score 1–2 was observed in most biopsies (21/29, 72%). The incidence of microsteatosis <50% and macrosteatosis <30% was prevalent in our series (24/29, 82% and 22/29, 76%). Lobular infiltration was found in most biopsies (15/24, 63%), while hepatocellular focal necrosis was documented in the 45% (11/24). Severe IRI was found in a small percentage of uDCDs (4/24, 16%).

Conclusion

In our series, liver biopsy in uDCDs may provide clinicians with two different kinds of information. The first one may be mainly related to comorbidities and chronic damages, as indicated by the presence (and percentages) of micro/macrosteatosis and Ishak grading/score. The second one might provide insights into the ischemic-reperfusion injury of the liver, that is it might be related to the uDCD process itself.

背景:循环性死亡后不受控制的供体被认为是一个潜在的供体池。目前尚无关于udcd患者肝活检结果的数据。我们的目的是评估2019年至2023年连续入住本中心的udcd的肝活检结果。方法:选取2019 - 2023年在我中心连续收治的29例uDCD患者。所有udcd患者在器官获取期间均行肝活检。结果:从心脏骤停到常温区域灌注(NRP)运行的中位时间为144 min, NRP持续时间中位为6 h。12例(12/ 29,41 %)供肝被取出但未移植,10例(10/ 29,35 %)供肝被移植。在7例udcd中,肝脏未被取出(24%)。大多数活检组织的Ishak评分为1-2分(21/29,72%)。结论:在我们的研究中,udcd患者的肝活检可能为临床医生提供两种不同的信息。第一种可能主要与合并症和慢性损害有关,如微/大脂肪变性和Ishak分级/评分的存在(和百分比)所示。第二种可能为肝脏缺血再灌注损伤提供新的见解,即它可能与uDCD过程本身有关。
{"title":"The Role of Liver Biopsy Findings in Uncontrolled Donation After Circulatory Death a 4-Year Single-Center Experience","authors":"Luca Novelli,&nbsp;Chiara Lazzeri,&nbsp;Davide Ghinolfi,&nbsp;Manuela Bonizzoli,&nbsp;Tiziana Tatti,&nbsp;Luca Messerini,&nbsp;Giuseppe Feltrin,&nbsp;Adriano Peris","doi":"10.1111/ctr.70431","DOIUrl":"10.1111/ctr.70431","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Uncontrolled donors after circulatory death (uDCDs) are recognized as a potential donor pool. No data are so far available on liver biopsy findings in uDCDs. We aimed at assessing liver biopsy findings in uDCDs consecutively admitted to our Center from 2019 to 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Twenty nine utilized uDCD consecutively admitted at our Center from 2019 to 2023 were included. Liver biopsies were performed during organ procurement in all uDCDs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median time from cardiac arrest to normothermic regional perfusion (NRP) run was 144 min, while the median NRP duration was 6 h. The liver was retrieved but not transplanted in 12 donors (12/29, 41%) and transplanted in 10 donors (10/29, 35%). In 7 uDCDs, livers were not retrieved (24%). Ishak grading score 1–2 was observed in most biopsies (21/29, 72%). The incidence of microsteatosis &lt;50% and macrosteatosis &lt;30% was prevalent in our series (24/29, 82% and 22/29, 76%). Lobular infiltration was found in most biopsies (15/24, 63%), while hepatocellular focal necrosis was documented in the 45% (11/24). Severe IRI was found in a small percentage of uDCDs (4/24, 16%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In our series, liver biopsy in uDCDs may provide clinicians with two different kinds of information. The first one may be mainly related to comorbidities and chronic damages, as indicated by the presence (and percentages) of micro/macrosteatosis and Ishak grading/score. The second one might provide insights into the ischemic-reperfusion injury of the liver, that is it might be related to the uDCD process itself.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA-DR Matching in Kidney Transplantation: Ethnic Disparities in Clinical Benefit and Policy Implications From a UK Registry Analysis 肾移植中的HLA-DR匹配:来自英国注册分析的临床获益和政策意义的种族差异。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-06 DOI: 10.1111/ctr.70429
Hatem Ali, David Briggs, Nithya Krishnan

Background

The UK Kidney Allocation Scheme (KAS) prioritizes organ allocation based on HLA mismatches, assigning the greatest weight to HLA-DR compatibility. However, the clinical relevance of this approach across different ethnicities in the era of modern immunosuppression remains uncertain.

Methods

We conducted a retrospective cohort study of 25 094 adult deceased donor kidney transplants in the United Kingdom between 2008 and 2020. Using competing risk Cox regression, we evaluated the impact of individual HLA locus mismatches and grouped mismatch levels (as defined by UK-KAS) on graft survival. Subgroup analyses by ethnicity were performed, and the relationship between HLA mismatches and acute rejection was assessed using logistic regression.

Results

A single HLA-DR mismatch was significantly associated with graft failure (SHR 1.119, 95% CI 1.035–1.211, p = 0.005), while mismatches at the A, B, and DQ loci were not. In subgroup analyses, HLA-DR mismatching was predictive of graft failure in Asian recipients but not in Black recipients. Black patients also exhibited higher rates of mismatching at all loci. DQ mismatches were associated with early acute rejection but did not predict long-term graft failure. Ten-year graft survival was 13% less with one HLA DR mismatch, and 17% less with 2 HLA DR mismatch, in comparison to zero DR mismatch. The four-level HLA mismatch grouping used by UK-KAS stratified risk incrementally, with levels 3 and 4 associated with 13% and 19% higher failure risk, respectively.

Conclusions

HLA-DR matching improves graft survival overall but offers limited benefit in Black recipients, likely due to low-resolution typing inadequately capturing immunological compatibility across ethnic lines. The current UK-KAS scoring system may inadvertently disadvantage ethnic minorities by delaying transplantation for matches that confer minimal benefit. Our findings support incorporating ethnicity-specific considerations into kidney allocation policy to promote equity and optimize outcomes.

背景:英国肾脏分配方案(KAS)优先考虑基于HLA不匹配的器官分配,赋予HLA- dr兼容性最大的权重。然而,在现代免疫抑制时代,这种方法在不同种族之间的临床相关性仍然不确定。方法:我们对2008年至2020年间英国25094例成人死亡供体肾移植进行了回顾性队列研究。使用竞争风险Cox回归,我们评估了个体HLA位点不匹配和分组不匹配水平(由UK-KAS定义)对移植物存活的影响。按种族进行亚组分析,并使用逻辑回归评估HLA错配与急性排斥反应之间的关系。结果:单个HLA-DR不匹配与移植物失败显著相关(SHR 1.119, 95% CI 1.035-1.211, p = 0.005),而A、B和DQ位点不匹配。在亚组分析中,HLA-DR错配可预测亚洲受者的移植物衰竭,而非黑人受者。黑人患者在所有位点上也表现出更高的不匹配率。DQ错配与早期急性排斥反应有关,但不能预测长期移植物衰竭。与零DR不匹配相比,一次HLA DR不匹配的移植10年生存率低13%,两次HLA DR不匹配的移植10年生存率低17%。UK-KAS使用的4级HLA错配分组将风险逐级分层,3级和4级分别与13%和19%的高失败风险相关。结论:HLA-DR匹配总体上提高了移植物存活率,但在黑人受者中提供的益处有限,可能是由于低分辨率分型不能充分捕获跨种族的免疫相容性。目前的UK-KAS评分系统可能会在不经意间对少数民族造成不利影响,因为它推迟了移植的时间,而这些移植带来的好处微乎其微。我们的研究结果支持将特定种族的考虑纳入肾脏分配政策,以促进公平和优化结果。
{"title":"HLA-DR Matching in Kidney Transplantation: Ethnic Disparities in Clinical Benefit and Policy Implications From a UK Registry Analysis","authors":"Hatem Ali,&nbsp;David Briggs,&nbsp;Nithya Krishnan","doi":"10.1111/ctr.70429","DOIUrl":"10.1111/ctr.70429","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The UK Kidney Allocation Scheme (KAS) prioritizes organ allocation based on HLA mismatches, assigning the greatest weight to HLA-DR compatibility. However, the clinical relevance of this approach across different ethnicities in the era of modern immunosuppression remains uncertain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study of 25 094 adult deceased donor kidney transplants in the United Kingdom between 2008 and 2020. Using competing risk Cox regression, we evaluated the impact of individual HLA locus mismatches and grouped mismatch levels (as defined by UK-KAS) on graft survival. Subgroup analyses by ethnicity were performed, and the relationship between HLA mismatches and acute rejection was assessed using logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A single HLA-DR mismatch was significantly associated with graft failure (SHR 1.119, 95% CI 1.035–1.211, <i>p</i> = 0.005), while mismatches at the A, B, and DQ loci were not. In subgroup analyses, HLA-DR mismatching was predictive of graft failure in Asian recipients but not in Black recipients. Black patients also exhibited higher rates of mismatching at all loci. DQ mismatches were associated with early acute rejection but did not predict long-term graft failure. Ten-year graft survival was 13% less with one HLA DR mismatch, and 17% less with 2 HLA DR mismatch, in comparison to zero DR mismatch. The four-level HLA mismatch grouping used by UK-KAS stratified risk incrementally, with levels 3 and 4 associated with 13% and 19% higher failure risk, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HLA-DR matching improves graft survival overall but offers limited benefit in Black recipients, likely due to low-resolution typing inadequately capturing immunological compatibility across ethnic lines. The current UK-KAS scoring system may inadvertently disadvantage ethnic minorities by delaying transplantation for matches that confer minimal benefit. Our findings support incorporating ethnicity-specific considerations into kidney allocation policy to promote equity and optimize outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12771550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Letter to the Editor by Kumar, et al. 对Kumar等人给编辑的信的回应。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-06 DOI: 10.1111/ctr.70440
Babak J. Orandi, Mara A. McAdams-DeMarco
{"title":"Response to Letter to the Editor by Kumar, et al.","authors":"Babak J. Orandi,&nbsp;Mara A. McAdams-DeMarco","doi":"10.1111/ctr.70440","DOIUrl":"10.1111/ctr.70440","url":null,"abstract":"","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis 肝移植术后原发性硬化性胆管炎复发的危险因素:多中心回顾性分析。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-06 DOI: 10.1111/ctr.70436
Gupse Adali, Sencan Acar, Murat Harputluoğlu, Tonguç Utku Yılmaz, Hamdi Karakayalı, Zülal Istemihan, Sabahattin Kaymakoğlu, Çiğdem Arıkan, Murat Akyıldız, Nilay Daniş, Mehmet Akça, Mesut Akarsu, Dilara Turan Gökçe, Derya Arı, Meral Akdoğan Kayhan, Haydar Adanır, Dinç Dinçer, Elvan Işık, İlker Turan, Fulya Günşar, Volkan Yılmaz, Hale Gökcan, Zeki Karasu, Ramazan Idilman

Background and Aims

Primary sclerosing cholangitis recurrence (rPSC) after liver transplantation (LT) is common; however, the factors contributing to rPSC are poorly understood. This study aimed to identify the risk factors for rPSC after LT and determine whether donor type affects rPSC.

Methods

A multicenter retrospective cohort analysis was conducted on 174 patients with PSC who underwent LT between January 2000 and January 2024. Multivariable Cox models were used to evaluate risk factors for rPSC. The rPSC risk for living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT) recipients was compared using Kaplan-Meier survival curves and log-rank tests.

Results

Of the 174 recipients, 144 (83%) underwent LDLT and 30 (17%) underwent DDLT. Sixty-four (37%) had inflammatory bowel disease (IBD) prior to LT. Thirty-three patients (19%) had rPSC after LT. The median time to rPSC was 28 months (IQR 6-252). Patients with rPSC were younger at the time of PSC diagnosis, and had a higher prevalence of biliary complications after LT and concomitant IBD than those without recurrence. Multivariable Cox regression identified LDLT (HR 3.92, 95% CI 1.06–14.51, p = 0.041), biliary complications (HR 2.18, 95% CI 1.05–4.54, p = 0.037), IBD (HR 2.42, 95% CI 1.20–4.89, p = 0.013), and acute cellular rejection (HR 2.43, 95% CI 1.08–5.48, p = 0.032) as independent risk factors for rPSC.

Conclusions

This multicenter study identified LDLT, acute cellular rejection, IBD, and biliary complications as independent risk factors for rPSC. These findings underscore the need for individualized post-transplant surveillance and provide important considerations for graft selection and perioperative management in patients with PSC, particularly in settings where LDLT is predominant.

背景与目的:肝移植术后原发性硬化性胆管炎复发(rPSC)较为常见;然而,导致rPSC的因素却知之甚少。本研究旨在确定肝移植后rPSC的危险因素,并确定供体类型是否影响rPSC。方法:对2000年1月至2024年1月间行肝移植的174例PSC患者进行多中心回顾性队列分析。采用多变量Cox模型评价rPSC的危险因素。采用Kaplan-Meier生存曲线和log-rank检验比较活体供肝移植(LDLT)和已故供肝移植(DDLT)受者的rPSC风险。结果:174名受者中,144名(83%)接受了LDLT, 30名(17%)接受了DDLT。64名(37%)患者在lt前患有炎症性肠病(IBD), 33名(19%)患者在lt后患有rPSC。中位时间为28个月(IQR 6-252)。rPSC患者在诊断时年龄较小,与无复发的患者相比,LT后胆道并发症和合并IBD的发生率更高。多变量Cox回归确定LDLT (HR 3.92, 95% CI 1.06-14.51, p = 0.041)、胆道并发症(HR 2.18, 95% CI 1.05-4.54, p = 0.037)、IBD (HR 2.42, 95% CI 1.20-4.89, p = 0.013)和急性细胞排斥反应(HR 2.43, 95% CI 1.08-5.48, p = 0.032)是rPSC的独立危险因素。结论:这项多中心研究确定了LDLT、急性细胞排斥反应、IBD和胆道并发症是rPSC的独立危险因素。这些发现强调了个体化移植后监测的必要性,并为PSC患者的移植物选择和围手术期管理提供了重要的考虑因素,特别是在以LDLT为主的环境中。
{"title":"Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis","authors":"Gupse Adali,&nbsp;Sencan Acar,&nbsp;Murat Harputluoğlu,&nbsp;Tonguç Utku Yılmaz,&nbsp;Hamdi Karakayalı,&nbsp;Zülal Istemihan,&nbsp;Sabahattin Kaymakoğlu,&nbsp;Çiğdem Arıkan,&nbsp;Murat Akyıldız,&nbsp;Nilay Daniş,&nbsp;Mehmet Akça,&nbsp;Mesut Akarsu,&nbsp;Dilara Turan Gökçe,&nbsp;Derya Arı,&nbsp;Meral Akdoğan Kayhan,&nbsp;Haydar Adanır,&nbsp;Dinç Dinçer,&nbsp;Elvan Işık,&nbsp;İlker Turan,&nbsp;Fulya Günşar,&nbsp;Volkan Yılmaz,&nbsp;Hale Gökcan,&nbsp;Zeki Karasu,&nbsp;Ramazan Idilman","doi":"10.1111/ctr.70436","DOIUrl":"10.1111/ctr.70436","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Primary sclerosing cholangitis recurrence (rPSC) after liver transplantation (LT) is common; however, the factors contributing to rPSC are poorly understood. This study aimed to identify the risk factors for rPSC after LT and determine whether donor type affects rPSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A multicenter retrospective cohort analysis was conducted on 174 patients with PSC who underwent LT between January 2000 and January 2024. Multivariable Cox models were used to evaluate risk factors for rPSC. The rPSC risk for living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT) recipients was compared using Kaplan-Meier survival curves and log-rank tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 174 recipients, 144 (83%) underwent LDLT and 30 (17%) underwent DDLT. Sixty-four (37%) had inflammatory bowel disease (IBD) prior to LT. Thirty-three patients (19%) had rPSC after LT. The median time to rPSC was 28 months (IQR 6-252). Patients with rPSC were younger at the time of PSC diagnosis, and had a higher prevalence of biliary complications after LT and concomitant IBD than those without recurrence. Multivariable Cox regression identified LDLT (HR 3.92, 95% CI 1.06–14.51, <i>p</i> = 0.041), biliary complications (HR 2.18, 95% CI 1.05–4.54, <i>p</i> = 0.037), IBD (HR 2.42, 95% CI 1.20–4.89, <i>p</i> = 0.013), and acute cellular rejection (HR 2.43, 95% CI 1.08–5.48, <i>p</i> = 0.032) as independent risk factors for rPSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This multicenter study identified LDLT, acute cellular rejection, IBD, and biliary complications as independent risk factors for rPSC. These findings underscore the need for individualized post-transplant surveillance and provide important considerations for graft selection and perioperative management in patients with PSC, particularly in settings where LDLT is predominant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Efficacy of Apixaban in HeartMate 3 Left Ventricular Assist Devices 阿哌沙班在HeartMate 3左心室辅助装置中的安全性和有效性。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-06 DOI: 10.1111/ctr.70430
Ashwin A. Pillai, Aryan Mehta, Balaphanidhar Mogga, Cesar Rubio-Ramos, Katrina F. Etts, Kelly McNamara-Diorio, Amanda Maxfield, Dawn Surprenant, Jason Gluck, Abhishek Jaiswal

Background

Warfarin, the anticoagulant of choice for durable left ventricular assist devices (LVADs), has a narrow therapeutic index and extensive pharmacologic interactions that make dose optimization challenging. Inadequate time in the therapeutic range increases the risk of thrombotic and hemorrhagic complications. We sought to evaluate the safety and efficacy of apixaban as an alternative anticoagulant for HeartMate (HM) 3 LVADs.

Methods

We analyzed data for patients with HM3 LVADs treated at our center between 2018 and 2024, comparing thromboembolic and hemorrhagic events between patients receiving warfarin and those who transitioned to apixaban due to adverse events or labile therapeutic responses on warfarin.

Results

We included 47 patients, 16 of whom remained on warfarin, while 31 transitioned to apixaban. Both cohorts had identical baseline characteristics. Rates of all-cause bleeding per 100 patient-years were similar for warfarin (33) and apixaban (29), p = 0.24. The relative risk (RR) of major bleeding within the first 3 months of anticoagulation was significantly lower with apixaban—RR 0.08 (95% CI, 0.01–0.65, p = 0.01), with an incidence rate of 6.4% on apixaban versus 43.8% on warfarin. All-cause bleeding occurred less frequently with apixaban at 32% compared to 68.8%—RR 0.14 (95% CI 0.03–0.62, p = 0.009). Hemocompatibility improved in the apixaban group, evidenced by an increase in hemoglobin (11 ± 2 to 12 ± 2 g/dL, p < 0.001) and a decrease in lactate dehydrogenase (427 ± 129 to 221 ± 83 U/L, p < 0.001). Thrombotic events were identical.

Conclusion

In patients with HM3 LVADs, apixaban may be a safe and clinically effective alternative to warfarin.

背景:华法林是持久左心室辅助装置(lvad)的首选抗凝剂,其治疗指数较窄,药理学相互作用广泛,这使得剂量优化具有挑战性。治疗时间不足会增加血栓和出血性并发症的风险。我们试图评估阿哌沙班作为心脏伴侣(HM) 3型lvad的替代抗凝剂的安全性和有效性。方法:我们分析了2018年至2024年在本中心治疗的HM3 lvad患者的数据,比较了接受华法林治疗的患者与因华法林不良事件或治疗反应不稳定而改用阿哌沙班的患者的血栓栓塞和出血事件。结果:我们纳入了47例患者,其中16例继续使用华法林,31例改用阿哌沙班。两个队列具有相同的基线特征。华法林(33例)和阿哌沙班(29例)的全因出血率相似,p = 0.24。阿哌沙班抗凝治疗前3个月内发生大出血的相对危险度(RR)显著低于阿哌沙班,RR为0.08 (95% CI, 0.01 ~ 0.65, p = 0.01),阿哌沙班的发生率为6.4%,华法林的发生率为43.8%。阿哌沙班组全因出血发生率为32%,低于68.8% (rr 0.14, 95% CI 0.03-0.62, p = 0.009)。阿哌沙班组血液相容性改善,血红蛋白升高(11±2 ~ 12±2 g/dL), p结论:在HM3 lvad患者中,阿哌沙班可能是一种安全且临床有效的华法林替代品。
{"title":"Safety and Efficacy of Apixaban in HeartMate 3 Left Ventricular Assist Devices","authors":"Ashwin A. Pillai,&nbsp;Aryan Mehta,&nbsp;Balaphanidhar Mogga,&nbsp;Cesar Rubio-Ramos,&nbsp;Katrina F. Etts,&nbsp;Kelly McNamara-Diorio,&nbsp;Amanda Maxfield,&nbsp;Dawn Surprenant,&nbsp;Jason Gluck,&nbsp;Abhishek Jaiswal","doi":"10.1111/ctr.70430","DOIUrl":"10.1111/ctr.70430","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Warfarin, the anticoagulant of choice for durable left ventricular assist devices (LVADs), has a narrow therapeutic index and extensive pharmacologic interactions that make dose optimization challenging. Inadequate time in the therapeutic range increases the risk of thrombotic and hemorrhagic complications. We sought to evaluate the safety and efficacy of apixaban as an alternative anticoagulant for HeartMate (HM) 3 LVADs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed data for patients with HM3 LVADs treated at our center between 2018 and 2024, comparing thromboembolic and hemorrhagic events between patients receiving warfarin and those who transitioned to apixaban due to adverse events or labile therapeutic responses on warfarin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included 47 patients, 16 of whom remained on warfarin, while 31 transitioned to apixaban. Both cohorts had identical baseline characteristics. Rates of all-cause bleeding per 100 patient-years were similar for warfarin (33) and apixaban (29), <i>p</i> = 0.24. The relative risk (RR) of major bleeding within the first 3 months of anticoagulation was significantly lower with apixaban—RR 0.08 (95% CI, 0.01–0.65, <i>p</i> = 0.01), with an incidence rate of 6.4% on apixaban versus 43.8% on warfarin. All-cause bleeding occurred less frequently with apixaban at 32% compared to 68.8%—RR 0.14 (95% CI 0.03–0.62, <i>p</i> = 0.009). Hemocompatibility improved in the apixaban group, evidenced by an increase in hemoglobin (11 ± 2 to 12 ± 2 g/dL, <i>p</i> &lt; 0.001) and a decrease in lactate dehydrogenase (427 ± 129 to 221 ± 83 U/L, <i>p</i> &lt; 0.001). Thrombotic events were identical.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients with HM3 LVADs, apixaban may be a safe and clinically effective alternative to warfarin.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Natural Language Processing to Characterize Early Steps in the Kidney Transplant Evaluation Process Documented in the National Veterans Affairs Electronic Health Record. 使用自然语言处理来描述国家退伍军人事务电子健康记录中记录的肾脏移植评估过程的早期步骤。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-01 DOI: 10.1111/ctr.70441
Hannah Eyre, David K Prince, Sandra Abrahamson, Richard K Blankenhorn, Evan P Carey, Ryan J Laundry, Whitney Showalter, Jeffrey Todd-Stenberg, Ann M O'Hare, Catherine R Butler

Background: Efforts to identify barriers and improve access to kidney transplantation in the United States are limited by a lack of population-level data on early steps in the transplant evaluation process.

Methods: We used a rule-based natural language processing (NLP) approach with clinical notes in the US Veterans Affairs Healthcare System (VA) electronic health record (EHR) and linkage with the United States Renal Data System registry to characterize sequential steps in the kidney transplant evaluation process. Adults with advanced kidney disease (estimated glomerular filtration rate ≤20 mL/min/1.73m2) from 1/1/2012-12/31/2019 who were receiving care within the VA were followed through 12/31/2021.

Results: Among 45,174 cohort members, the median age was 71 (IQR 64, 80) years, and 97.2% were men. There was documentation of kidney transplant being mentioned as a treatment option for 46.3% of cohort members, 28.2% engaged in some type of evaluation for transplant, and 8.4% were referred to and 5.4% evaluated at a VA kidney transplant center. 6.9% of cohort members were added to the national deceased donor waitlist and 3.1% received a kidney transplant. Compared with events identified through EHR chart search and manual review by two clinicians, NLP identified events within 90 days with a precision of 0.82-0.94 and recall of 0.56-0.89.

Conclusion: These results illuminate the substantial proportion of patients who engage in early steps in the kidney transplant evaluation process. The work also demonstrates that NLP can accurately identify these key steps in the process as documented in patients' EHRs.

背景:由于缺乏移植评估过程中早期步骤的人口水平数据,在美国识别障碍和改善肾移植可及性的努力受到限制。方法:我们使用基于规则的自然语言处理(NLP)方法,结合美国退伍军人事务医疗保健系统(VA)电子健康记录(EHR)中的临床记录,并与美国肾脏数据系统注册表联系,以表征肾移植评估过程中的顺序步骤。2012年1月1日至2019年12月31日期间在VA内接受治疗的晚期肾病成人(估计肾小球滤过率≤20 mL/min/1.73m2)随访至2021年12月31日。结果:在45,174名队列成员中,中位年龄为71岁(IQR 64,80)岁,97.2%为男性。有文献记载,46.3%的队列成员提到肾移植作为一种治疗选择,28.2%的人参与了某种类型的移植评估,8.4%的人被推荐到VA肾移植中心,5.4%的人在VA肾移植中心接受评估。6.9%的队列成员加入了全国已故捐赠者等待名单,3.1%的人接受了肾脏移植。与通过EHR图表搜索和两位临床医生手动审查识别的事件相比,NLP识别90天内的事件,精度为0.82-0.94,召回率为0.56-0.89。结论:这些结果阐明了在肾移植评估过程中参与早期步骤的大量患者。这项工作还表明,NLP可以准确地识别患者电子病历中记录的过程中的这些关键步骤。
{"title":"Using Natural Language Processing to Characterize Early Steps in the Kidney Transplant Evaluation Process Documented in the National Veterans Affairs Electronic Health Record.","authors":"Hannah Eyre, David K Prince, Sandra Abrahamson, Richard K Blankenhorn, Evan P Carey, Ryan J Laundry, Whitney Showalter, Jeffrey Todd-Stenberg, Ann M O'Hare, Catherine R Butler","doi":"10.1111/ctr.70441","DOIUrl":"10.1111/ctr.70441","url":null,"abstract":"<p><strong>Background: </strong>Efforts to identify barriers and improve access to kidney transplantation in the United States are limited by a lack of population-level data on early steps in the transplant evaluation process.</p><p><strong>Methods: </strong>We used a rule-based natural language processing (NLP) approach with clinical notes in the US Veterans Affairs Healthcare System (VA) electronic health record (EHR) and linkage with the United States Renal Data System registry to characterize sequential steps in the kidney transplant evaluation process. Adults with advanced kidney disease (estimated glomerular filtration rate ≤20 mL/min/1.73m<sup>2</sup>) from 1/1/2012-12/31/2019 who were receiving care within the VA were followed through 12/31/2021.</p><p><strong>Results: </strong>Among 45,174 cohort members, the median age was 71 (IQR 64, 80) years, and 97.2% were men. There was documentation of kidney transplant being mentioned as a treatment option for 46.3% of cohort members, 28.2% engaged in some type of evaluation for transplant, and 8.4% were referred to and 5.4% evaluated at a VA kidney transplant center. 6.9% of cohort members were added to the national deceased donor waitlist and 3.1% received a kidney transplant. Compared with events identified through EHR chart search and manual review by two clinicians, NLP identified events within 90 days with a precision of 0.82-0.94 and recall of 0.56-0.89.</p><p><strong>Conclusion: </strong>These results illuminate the substantial proportion of patients who engage in early steps in the kidney transplant evaluation process. The work also demonstrates that NLP can accurately identify these key steps in the process as documented in patients' EHRs.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":"e70441"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Lung Waitlist Score (PLWS): A Score to Predict Waitlist Time for Pediatric Lung Transplant Candidates. 儿童肺等待名单评分(PLWS):预测儿童肺移植候选人等待名单时间的评分。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-01 DOI: 10.1111/ctr.70454
Jose Ramirez, Spoorthi Kamepalli, Abbas Rana

Background: In pediatric lung transplantation, the ability to estimate the projected waiting time could be particularly helpful for candidates and physicians. A score to predict waiting time has yet to be developed in this field. The purpose of this study was to create a score that predicts waitlist time for pediatric patients who are listed for lung transplantation.

Methods: A retrospective analysis was performed with publicly available de-identified OPTN lung transplant data from March 8, 2019, to March 8, 2025. After applying our exclusionary criteria, the sample included 218 pediatric patients, whom we divided into training and testing groups based on the implementation of the CAS. Univariable and multivariable analyses on the training group of pediatric patients identified independent recipient risk factors for the time spent on the waitlist. This model was used to make our score, the pediatric lung waitlist score (PLWS), which was then applied to the testing group to examine its validity.

Results: Five recipient factors were independently associated with time to transplant: adolescence, ECMO support, residence in OPTN Region 4, residence in Region 8, and very high oxygen supplementation (>15 LPM). The resulting score demonstrated a c-statistic of 0.71 in the training cohort and 0.73 in the testing cohort.

Conclusion: We identified five recipient characteristics that significantly predict pediatric lung transplant waitlist duration and incorporated them into a prognostic score, the PLWS, derived from a Cox proportional hazards model.

背景:在儿童肺移植中,估计预计等待时间的能力对候选者和医生特别有帮助。在这一领域,预测等待时间的分数尚未开发。本研究的目的是建立一个分数,预测等待肺移植的儿科患者的等待时间。方法:对2019年3月8日至2025年3月8日公开获取的去识别OPTN肺移植数据进行回顾性分析。在应用我们的排除标准后,样本包括218名儿科患者,我们根据CAS的实施情况将其分为培训组和测试组。对儿科患者训练组的单变量和多变量分析确定了在等待名单上花费时间的独立受体风险因素。该模型用于制作我们的评分,即儿科肺部等待列表评分(PLWS),然后将其应用于试验组以检验其有效性。结果:5个受体因素与移植时间独立相关:青春期、ECMO支持、居住在OPTN 4区、居住在8区、高氧补充(>15 LPM)。结果显示,训练组的c统计量为0.71,测试组为0.73。结论:我们确定了五个显著预测儿童肺移植等待名单持续时间的受体特征,并将其纳入预后评分PLWS,该评分来自Cox比例风险模型。
{"title":"Pediatric Lung Waitlist Score (PLWS): A Score to Predict Waitlist Time for Pediatric Lung Transplant Candidates.","authors":"Jose Ramirez, Spoorthi Kamepalli, Abbas Rana","doi":"10.1111/ctr.70454","DOIUrl":"https://doi.org/10.1111/ctr.70454","url":null,"abstract":"<p><strong>Background: </strong>In pediatric lung transplantation, the ability to estimate the projected waiting time could be particularly helpful for candidates and physicians. A score to predict waiting time has yet to be developed in this field. The purpose of this study was to create a score that predicts waitlist time for pediatric patients who are listed for lung transplantation.</p><p><strong>Methods: </strong>A retrospective analysis was performed with publicly available de-identified OPTN lung transplant data from March 8, 2019, to March 8, 2025. After applying our exclusionary criteria, the sample included 218 pediatric patients, whom we divided into training and testing groups based on the implementation of the CAS. Univariable and multivariable analyses on the training group of pediatric patients identified independent recipient risk factors for the time spent on the waitlist. This model was used to make our score, the pediatric lung waitlist score (PLWS), which was then applied to the testing group to examine its validity.</p><p><strong>Results: </strong>Five recipient factors were independently associated with time to transplant: adolescence, ECMO support, residence in OPTN Region 4, residence in Region 8, and very high oxygen supplementation (>15 LPM). The resulting score demonstrated a c-statistic of 0.71 in the training cohort and 0.73 in the testing cohort.</p><p><strong>Conclusion: </strong>We identified five recipient characteristics that significantly predict pediatric lung transplant waitlist duration and incorporated them into a prognostic score, the PLWS, derived from a Cox proportional hazards model.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":"e70454"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opioid Use as a Predictor of Pancreas Transplant Outcomes. 阿片类药物使用作为胰腺移植结果的预测因子。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-01 DOI: 10.1111/ctr.70453
Youngmin Ko, Eunbyeol Cho, Hye Eun Kwon, Jin-Myung Kim, Sung Shin, Young Hoon Kim, Edward Choi, Byunghyun Choi, Hyunwook Kwon

Background: Posttransplant opioid dependence has been linked to adverse outcomes in solid organ transplantation, but its impact on pancreas transplantation is underexplored.

Methods: This retrospective study analyzed 193 PTA/PAK recipients from Asan Medical Center (AMC) (2010-2022) and externally validated results in 77 recipients from Pusan National University Yangsan Hospital (PNUYH) (2015-2022). Posttransplant opioid dependence was defined as ≥ 10 opioid prescriptions between 3 and 12 months posttransplant. Logistic regression and three ML algorithms (CatBoost, XGBoost, and LightGBM) were used to identify risk factors and predict 5-year graft survival.

Results: Posttransplant opioid dependence (OR 2.87, p = 0.005) independently predicted 5-year graft failure, along with pre-transplant retinopathy, bladder drainage, and lower BMI. ML models showed favorable internal AUROC (0.695-0.719) and moderate external AUROC (0.649-0.671). Opioid dependence consistently ranked among top predictive features across models.

Conclusions: Posttransplant opioid dependence is a significant predictor of graft failure after pancreas transplantation. Incorporating this variable into ML models may enhance risk stratification and candidate selection.

背景:移植后阿片类药物依赖与实体器官移植的不良结果有关,但其对胰腺移植的影响尚未得到充分探讨。方法:回顾性分析峨山医疗中心(AMC)(2010-2022年)193例PTA/PAK患者和釜山国立大学梁山医院(PNUYH)(2015-2022年)77例外部验证患者的结果。移植后阿片类药物依赖定义为移植后3至12个月期间阿片类药物处方≥10张。使用逻辑回归和三种ML算法(CatBoost、XGBoost和LightGBM)来识别危险因素并预测移植物的5年生存率。结果:移植后阿片类药物依赖(OR 2.87, p = 0.005)独立预测5年移植失败,以及移植前视网膜病变、膀胱引流和较低的BMI。ML模型显示良好的内部AUROC(0.695-0.719)和中等的外部AUROC(0.649-0.671)。阿片类药物依赖一直是各模型的主要预测特征之一。结论:移植后阿片类药物依赖是胰腺移植后移植失败的重要预测因素。将这一变量纳入ML模型可以增强风险分层和候选人选择。
{"title":"Opioid Use as a Predictor of Pancreas Transplant Outcomes.","authors":"Youngmin Ko, Eunbyeol Cho, Hye Eun Kwon, Jin-Myung Kim, Sung Shin, Young Hoon Kim, Edward Choi, Byunghyun Choi, Hyunwook Kwon","doi":"10.1111/ctr.70453","DOIUrl":"https://doi.org/10.1111/ctr.70453","url":null,"abstract":"<p><strong>Background: </strong>Posttransplant opioid dependence has been linked to adverse outcomes in solid organ transplantation, but its impact on pancreas transplantation is underexplored.</p><p><strong>Methods: </strong>This retrospective study analyzed 193 PTA/PAK recipients from Asan Medical Center (AMC) (2010-2022) and externally validated results in 77 recipients from Pusan National University Yangsan Hospital (PNUYH) (2015-2022). Posttransplant opioid dependence was defined as ≥ 10 opioid prescriptions between 3 and 12 months posttransplant. Logistic regression and three ML algorithms (CatBoost, XGBoost, and LightGBM) were used to identify risk factors and predict 5-year graft survival.</p><p><strong>Results: </strong>Posttransplant opioid dependence (OR 2.87, p = 0.005) independently predicted 5-year graft failure, along with pre-transplant retinopathy, bladder drainage, and lower BMI. ML models showed favorable internal AUROC (0.695-0.719) and moderate external AUROC (0.649-0.671). Opioid dependence consistently ranked among top predictive features across models.</p><p><strong>Conclusions: </strong>Posttransplant opioid dependence is a significant predictor of graft failure after pancreas transplantation. Incorporating this variable into ML models may enhance risk stratification and candidate selection.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":"e70453"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Obesity and Metabolic Management in Kidney Transplantation: A Commentary on Metoyer et al. 在肾移植中整合肥胖和代谢管理:Metoyer等人的评论。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-01 DOI: 10.1111/ctr.70450
Vineeta Kumar, Sima Saberi, Hector Madariaga, Sabiha M Hussain
{"title":"Integrating Obesity and Metabolic Management in Kidney Transplantation: A Commentary on Metoyer et al.","authors":"Vineeta Kumar, Sima Saberi, Hector Madariaga, Sabiha M Hussain","doi":"10.1111/ctr.70450","DOIUrl":"https://doi.org/10.1111/ctr.70450","url":null,"abstract":"","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":"e70450"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplantation of Horseshoe Kidneys: Surgical Strategies and 15-Year Functional Outcomes From a Tertiary Center Experience. 马蹄形肾移植:三级中心经验的外科策略和15年功能结果。
IF 1.9 4区 医学 Q2 SURGERY Pub Date : 2026-01-01 DOI: 10.1111/ctr.70460
Francesco Nacchia, Riccardo Bertolo, Rostand Emmanuel Nguefouet Momo, Paola Donato, Gabriele Ugolini, Giovanni Corghi, Luigino Boschiero, Alessandro Antonelli

Background: Horseshoe kidney (HSK) is a rare congenital fusion anomaly that poses distinct anatomical and surgical challenges in kidney transplantation. Owing to its low incidence, evidence on long-term outcomes remains limited. This study reports a 20-year single-center experience with HSK transplantation, comparing en bloc and split grafts.

Methods: A retrospective analysis was conducted on six HSK transplants from deceased donors performed since January 2005. All recipients had end-stage renal disease and were undergoing dialysis at transplantation. The choice between en bloc or split implantation was based on vascular, isthmic, and collecting system anatomy. Primary outcomes included graft function, patient survival, and postoperative complications; secondary outcomes were delayed graft function (DGF) and long-term renal function. Descriptive statistical analysis was applied to perioperative and follow-up data, including serum creatinine (SCr) and graft survival up to 20 years.

Results: Among six recipients (three en bloc, three split), one en bloc recipient died on postoperative Day 3 due to bowel infarction. The remaining five patients showed immediate graft function, except one with DGF. At a mean follow-up of 14 years, all surviving recipients maintained satisfactory renal function (mean SCr = 130 µmol/L). No graft loss or major surgical complications were observed.

Conclusion: HSK transplantation, though technically demanding, represents a viable strategy to expand the donor pool. With careful anatomical assessment and surgical planning, both en bloc and split grafts can achieve excellent long-term outcomes. However, en bloc transplantation may entail greater procedural and spatial challenges, emphasizing the need for accurate recipient selection and size matching.

背景:马蹄肾(HSK)是一种罕见的先天性融合畸形,在肾移植中具有独特的解剖学和外科挑战。由于发病率低,关于长期结果的证据仍然有限。本研究报告了20年单中心HSK移植的经验,比较了整体移植和分裂移植。方法:回顾性分析2005年1月以来6例死亡供体HSK移植病例。所有受者均患有终末期肾病,并在移植时接受透析治疗。整体植入或分裂植入的选择是基于血管、峡部和收集系统解剖。主要结局包括移植物功能、患者生存和术后并发症;次要结果是延迟移植功能(DGF)和长期肾功能。描述性统计分析应用于围手术期和随访数据,包括血清肌酐(SCr)和移植存活长达20年。结果:6例受术者(3例整体,3例分开)中,1例整体受术者在术后第3天因肠梗死死亡。除1例DGF外,其余5例患者表现出立即的移植物功能。在平均14年的随访中,所有存活的受者保持了满意的肾功能(平均SCr = 130µmol/L)。未观察到移植物丢失或主要手术并发症。结论:HSK移植虽然在技术上要求很高,但却是一种扩大供体池的可行策略。通过仔细的解剖评估和手术计划,整体和分裂移植都可以获得良好的长期效果。然而,整体移植可能会带来更大的程序和空间挑战,强调需要准确的受体选择和大小匹配。
{"title":"Transplantation of Horseshoe Kidneys: Surgical Strategies and 15-Year Functional Outcomes From a Tertiary Center Experience.","authors":"Francesco Nacchia, Riccardo Bertolo, Rostand Emmanuel Nguefouet Momo, Paola Donato, Gabriele Ugolini, Giovanni Corghi, Luigino Boschiero, Alessandro Antonelli","doi":"10.1111/ctr.70460","DOIUrl":"https://doi.org/10.1111/ctr.70460","url":null,"abstract":"<p><strong>Background: </strong>Horseshoe kidney (HSK) is a rare congenital fusion anomaly that poses distinct anatomical and surgical challenges in kidney transplantation. Owing to its low incidence, evidence on long-term outcomes remains limited. This study reports a 20-year single-center experience with HSK transplantation, comparing en bloc and split grafts.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on six HSK transplants from deceased donors performed since January 2005. All recipients had end-stage renal disease and were undergoing dialysis at transplantation. The choice between en bloc or split implantation was based on vascular, isthmic, and collecting system anatomy. Primary outcomes included graft function, patient survival, and postoperative complications; secondary outcomes were delayed graft function (DGF) and long-term renal function. Descriptive statistical analysis was applied to perioperative and follow-up data, including serum creatinine (SCr) and graft survival up to 20 years.</p><p><strong>Results: </strong>Among six recipients (three en bloc, three split), one en bloc recipient died on postoperative Day 3 due to bowel infarction. The remaining five patients showed immediate graft function, except one with DGF. At a mean follow-up of 14 years, all surviving recipients maintained satisfactory renal function (mean SCr = 130 µmol/L). No graft loss or major surgical complications were observed.</p><p><strong>Conclusion: </strong>HSK transplantation, though technically demanding, represents a viable strategy to expand the donor pool. With careful anatomical assessment and surgical planning, both en bloc and split grafts can achieve excellent long-term outcomes. However, en bloc transplantation may entail greater procedural and spatial challenges, emphasizing the need for accurate recipient selection and size matching.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"40 1","pages":"e70460"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1